PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
Program Progress
PYC Therapeutics (ASX:PYC) announced significant advancements in its Phelan-McDermid Syndrome (PMS) program. The company has developed PYC-002, a drug candidate targeting the underlying cause of PMS by increasing SHANK3 gene expression in neurons.
Clinical Development
Recent in vitro studies demonstrated that PYC-002 restores SHANK3 gene expression to levels seen in unaffected individuals. Additionally, in vivo data showed effective control of target gene expression in key brain regions implicated in PMS. PYC plans to present these findings at the PMS Global Congress in Barcelona, Spain, between June 26-29, 2025. The PMS program is expected to enter clinical trials approximately twelve months from now, marking the fourth first-in-class drug candidate from PYC with disease-modifying potential advancing to human trials.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
